Objectives The optimum trough concentration of voriconazole for clinical response and
safety is controversial. The objective of this review was to determine the optimum trough …

Invasive aspergillosis has been mainly reported among immunocompromised patients
during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in …

Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to
evaluate its bronchopulmonary penetration. This study included 13 patients and showed …

The aim of this study was to establish antimicrobial susceptibility breakpoints for tilmicosin
against Haemophilus parasuis, which is an important pathogen of respiratory tract infections …

Critically ill patients may frequently experience severe invasive fungal infections. Biomarkers-
based diagnostic approaches give, at the same time, the possibility to early detect the …

Antibiotic resistance is a major public health threat worldwide. In particular, about 80% of
cystic fibrosis patients have chronic Pseudomonas aeruginosa (PA) lung infection resistant …

Voriconazole is one of the most used antifungal azoles against pulmonary aspergillosis.
Therapeutic drug monitoring (TDM) of the voriconazole concentration in plasma is …

Background Although voriconazole reached the bedside 10 years ago and became the
standard care in the treatment of invasive aspergillosis, reliable clinical breakpoints are still …

Lung transplant (LTx) patients have an increased risk of developing invasive fungal
infections (IFIs), particularly invasive aspergillosis. Rapid identification of the causative …

Aims: The pharmacokinetic (PK) profiles of voriconazole in intensive care unit (ICU) patients
differ from that in other patients. We aimed to develop a population pharmacokinetic …